Disc Medicine

Disc Medicine

Yahoo Finance • last month

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alle... Full story

Yahoo Finance • 3 months ago

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alle... Full story

Yahoo Finance • 3 months ago

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK in... Full story

Yahoo Finance • 3 months ago

Disc Medicine gets FDA onboard with approval path for rare disease therapy

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Disc Medicine (IRON [https://seekingalpha.com/symbol/IRON]) traded higher in the premarket on Tuesday after announcing that the company and the FDA have reac... Full story

Yahoo Finance • 3 months ago

חדשות למשקיעים ב- IRON: אם סבלתם הפסדים ב- Disc Medicine, Inc (נאסד"ק: IRON), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי הדין בנוגע לזכויותיכם

ניו יורק, June 03, 2026 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, ממשיך לחקור תביעות ניירות ערך פוטנציאליות מטעם בעלי המניות של Disc Medicine, Inc(נאסד"ק: IRON) הנובעו... Full story

Yahoo Finance • 3 months ago

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decisionBitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is bein... Full story

Yahoo Finance • 4 months ago

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from... Full story

Yahoo Finance • 4 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • 4 months ago

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

William Jacob Savage, Chief Medical Officer of Disc Medicine (NASDAQ:IRON), reported the sale of 5,731 shares of common stock in multiple open-market transactions on April 13, 2026, according to an SEC Form 4 filing. Transaction summary... Full story

Yahoo Finance • 5 months ago

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting fro... Full story

Yahoo Finance • 6 months ago

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment... Full story

Yahoo Finance • 6 months ago

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Jean M. Franchi, Chief Financial Officer of Disc Medicine(NASDAQ:IRON), executed open-market sales of 11,156 shares for approximately $720,000 across three transactions on Feb. 17 and Feb. 18, 2026, as disclosed in a recent SEC Form 4 fili... Full story

Yahoo Finance • 6 months ago

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

Disc Medicine (IRON) faces a delayed timeline for bitopertin after receiving a complete response let PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA... Full story

Yahoo Finance • 9 months ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOB... Full story

Yahoo Finance • 10 months ago

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story

Yahoo Finance • 10 months ago

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher (CNPV), a program des... Full story

Yahoo Finance • 10 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Friday afternoon with the NYSE Health Care Index climbing 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 10 months ago

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story

Yahoo Finance • 10 months ago

Achieve, Disc, Revolution among winners of initial FDA national priority vouchers

[US Food and Drug Administration (FDA)] Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]), Disc Medicine (NASDAQ:IRON [https://seekingalpha.com/symbol/IRON]), and Revolution Medicines (NASDAQ:RVMD [https://seeking... Full story